Related Experiment Video
Updated: Oct 2, 2025
08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
7.1K
A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.
Beibei Guo1, Yong Zang2,3
1Department of Experimental Statistics, 5779Louisiana State University, Baton Rouge, USA.
Statistical Methods in Medical Research
|February 22, 2022
Summary
This study introduces a new method, biomarker-based immunotherapy dose-finding (BSOI), to find the best immunotherapy dose for specific patient subgroups. BSOI effectively identifies and assigns patients to optimal subgroup-specific doses, outperforming traditional methods.
Area of Science:
- Oncology
- Immunology
- Biostatistics
Background:
- Immunotherapy harnesses the patient's immune system to fight cancer.
- Optimal dosing of immunotherapeutic agents can vary based on individual patient biomarker status.
- Personalized treatment strategies are crucial for maximizing immunotherapy efficacy.
Purpose of the Study:
- To develop a novel biomarker-based phase I/II dose-finding design for immunotherapy (BSOI).
- To identify subgroup-specific optimal doses by jointly modeling immune response, toxicity, and efficacy.
- To improve upon conventional dose-finding designs in immunotherapy clinical trials.
Main Methods:
- Proposed parsimonious and flexible statistical models for integrated outcome analysis.
- Utilized a utility function to quantify dose desirability.
- Implemented a two-stage dose-finding algorithm for subgroup-specific dose identification.
Main Results:
- The BSOI design demonstrated favorable operating characteristics in simulations.
- BSOI effectively selected and allocated patients to subgroup-specific optimal doses.
- The proposed design outperformed conventional dose-finding approaches.
Conclusions:
- The BSOI design offers an effective approach for personalized immunotherapy dosing.
- This method allows for tailored treatment strategies based on patient biomarkers.
- BSOI has the potential to enhance clinical trial efficiency and patient outcomes in immunotherapy.
